Protalix BioTherapeutics
(NYSEMKT) PLX
Protalix BioTherapeutics Financials at a Glance
Market Cap
$172.42M
Revenue (TTM)
$52.74M
Net Income (TTM)
$6.60M
EPS (TTM)
$-0.08
P/E Ratio
-25.33
Dividend
$0.00
Beta (Volatility)
0.70 (Low)
Dividend
$0.00
Beta (Volatility)
0.70 (Low)
Price
$2.15
Volume
14,938
Open
$2.09
Price
$2.15
Volume
14,938
Open
$2.09
Previous Close
$2.15
Daily Range
$2.09 - $2.20
52-Week Range
$1.32 - $3.19
Dividend
$0.00
Beta (Volatility)
0.70 (Low)
Price
$2.15
Volume
14,938
Open
$2.09
Previous Close
$2.15
Daily Range
$2.09 - $2.20
52-Week Range
$1.32 - $3.19
PLX News
Is This Orphan Drugmaker in Trouble?
5 of Last Week's Biggest Losers
PLX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Protalix BioTherapeutics
Industry
Biotechnology
Sector
Health CareEmployees
226
CEO
Dror Bashan, MBA
Website
www.protalix.comHeadquarters
Hackensack, NJ 07601, US
PLX Financials
Key Financial Metrics (TTM)
Gross Margin
49%
Operating Margin
-10%
Net Income Margin
-13%
Return on Equity
-14%
Return on Capital
-10%
Return on Assets
-8%
Earnings Yield
-3.95%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$172.42M
Shares Outstanding
80.57M
Volume
14.94K
Short Interest
0.00%
Avg. Volume
1.27M
Financials (TTM)
Gross Profit
$25.75M
Operating Income
$5.50M
EBITDA
$4.04M
Operating Cash Flow
$11.99M
Capital Expenditure
$1.64M
Free Cash Flow
$13.63M
Cash & ST Invst.
$14.68M
Total Debt
$8.32M
Protalix BioTherapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$9.12M
-49.9%
Gross Profit
$4.50M
-68.6%
Gross Margin
49.36%
N/A
Market Cap
$172.42M
N/A
Market Cap/Employee
$809.50K
N/A
Employees
213
N/A
Net Income
$5.50M
-184.8%
EBITDA
$5.25M
-168.6%
Quarterly Fundamentals
Net Cash
$6.36M
-78.3%
Accounts Receivable
$8.84M
+203.9%
Inventory
$25.73M
+21.1%
Long Term Debt
$6.94M
+72.3%
Short Term Debt
$1.38M
-7.7%
Return on Assets
-8.02%
N/A
Return on Invested Capital
-9.85%
N/A
Free Cash Flow
$3.27M
-8.4%
Operating Cash Flow
$2.03M
-49.1%